

Electronic Acknowledgement Receipt

EFS ID:	5893464
Application Number:	10785446
International Application Number:	
Confirmation Number:	1443
Title of Invention:	Method of treatment of disease using an adenosine A1 receptor antagonist
First Named Inventor/Applicant Name:	Lauren Otsuki
Customer Number:	00210
Filer:	Richard S. Parr/Phyllis Servon
Filer Authorized By:	Richard S. Parr
Attorney Docket Number:	NOV-ACV-00010
Receipt Date:	14-AUG-2009
Filing Date:	23-FEB-2004
Time Stamp:	16:14:58
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	no
------------------------	----

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Information Disclosure Statement (IDS) Filed (SB/08)	NOV_ACV_00010_US_IDS_For m_SB_08a.pdf	608055 <small>7af632ef6d6521e9559dbae6a46d8d7d6d1e51679e</small>	no	4

Warnings:

Information:

A U.S. Patent Number Citation or a U.S. Publication Number Citation is required in the Information Disclosure Statement (IDS) form for autoloading of data into USPTO systems. You may remove the form to add the required data in order to correct the Informational Message if you are citing U.S. References. If you chose not to include U.S. References, the image of the form will be processed and be made available within the Image File Wrapper (IFW) system. However, no data will be extracted from this form. Any additional data such as Foreign Patent Documents or Non Patent Literature will be manually reviewed and keyed into USPTO systems.

2	Transmittal Letter	00010_IDS_Ltr.pdf	370571 d8881e3824e0f73624052861e58f5141 5a25	no	2
Warnings:					
Information:					
3	Foreign Reference	EP0711772_.pdf	1138121 6a07188a2a90785d7295534bd5e089a7 6362	no	27
Warnings:					
Information:					
4	Foreign Reference	EP0415456B1.pdf	1359521 4d51347b2d800725edc243ab8a7bc18a 44234	no	39
Warnings:					
Information:					
5	Foreign Reference	EP0619316B1.pdf	1312661 db0151bf4f147852a7a3d81dc56af581956 ba0d3	no	29
Warnings:					
Information:					
6	Foreign Reference	WO9511904.pdf	1698827 2f906200c782243c22f592168db95e7679f 30bf	no	47
Warnings:					
Information:					
7	Foreign Reference	EP0711772A4SchRpt.pdf	108561 b7efb7d6dd28f7799bf5538468522425f 62c0d	no	4
Warnings:					
Information:					
8	Foreign Reference	EP0541120B1.pdf	963369 695045c27cdac08b012a6cdd45953a12a 6198e	no	32
Warnings:					
Information:					
Total Files Size (in bytes):			7559686		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.